Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis
NCT06869941, Recruiting, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis | ClinicalTrials.gov |
| NCT number | NCT06869941 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 100 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta | ClinicalTrials.gov |
| Conditions | Obesity | ClinicalTrials.gov |
| First posted | 2025-03-11 | ClinicalTrials.gov |
| Last updated | 2026-03-31 | ClinicalTrials.gov |
Registered outcomes 50
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Glycemic variability | 36 month | Mean and standard deviation of glucose measures in mg/dL using a CGM 10 days. | ClinicalTrials.gov |
| Primary | The percentage of time in glucose target range (glucose level 100mg/dl-125mg/dl) | 36 months | ClinicalTrials.gov | |
| Primary | The glycaemic risk measured with the low blood glucose index (LBGI) | 36 months | Low blood glucose index (LBGI) is a parameter that quantifies the risk of glycaemic. | ClinicalTrials.gov |
| Primary | The glycaemic variability measured with mean amplitude of glycaemic excursions (MAGE) | 36 months | measured in mg/dl | ClinicalTrials.gov |
| Primary | Minutes light sleep | 36 months | Mean and standard deviation of minutes' light sleep measures by activity and sleep tracker device. | ClinicalTrials.gov |
| Primary | Minutes deep sleep | 36 months | Mean and standard deviation of minutes' deep sleep measures by activity and sleep tracker device. | ClinicalTrials.gov |
| Primary | Minutes rapid eye movement (REM) | 36 months | Mean and standard deviation of minutes REM measures by activity and sleep tracker device. | ClinicalTrials.gov |
| Secondary | Audioverbal memory | 36 months | It will be measured by California Verbal Learning Test (CVLT). Minimum/maximum scale values (0-16), where 16 is a better audioverbal memory. | ClinicalTrials.gov |
| Secondary | Effect on gut microbiota | 36 months | Gut microbiota will be analysed by metagenomics and metabolomics. | ClinicalTrials.gov |
| Secondary | Visual memory | 36 months | It will be measured by Rey-Osterrieth Complex Figure. Minimum/maximum scale values (0-36), where 36 is a better visual memory. | ClinicalTrials.gov |
| Secondary | Depressive symptomatology | 36 months | It will be measured by Patient Health Questionnaire-9 (PHQ-9). Minimum/maximum scale values (0-27), where ≥ 20 is severe depression. | ClinicalTrials.gov |
| Secondary | Impulsivity | 36 months | It will be measured by Impulsive Behaviour Scale (UPPS-P). The test evaluates: Negative urgency (tendency to act rashly under extreme negative emotions), Lack of Premeditation (tendency to act without thinking), Lack of Perseverance (inability to remain focused on a task) and Sensation Seeking (tendency to seek out novel and thrilling experiences). All items are rated on a four point scale from 1 (strongly agree) to 4 (strongly disagree). | ClinicalTrials.gov |
| Secondary | Food Addiction | 36 months | It will be measured by Yale Food Addiction Scale. It is a symptom score from 0-11, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, for substance dependence. Food addiction is diagnosed if ≥3 symptoms are reported. | ClinicalTrials.gov |
| Secondary | Behavioural inhibition | 36 months | It will be measured by Sensitivity to Punishment and Sensitivity to Reward (SPSRQ). The scale of Sensitivity to Punishment is related to the behavioural inhibition system. It is made up of two subscales of 24 items each. For each subscale, the minimum score is 0 and the maximum score is 24, with higher scores indicating greater sensitivity to punishment or reward, respectively. | ClinicalTrials.gov |
| Secondary | Behavioural activation | 36 months | It will be measured by Sensitivity to Punishment and Sensitivity to Reward (SPSRQ). The reward sensitivity scale is related to the behavioural activation system. The questionnaire consists of two subscales of 24 items each. Each subscale ranges from 0 (minimum) to 24 (maximum), where a higher score indicates greater sensitivity to reward or punishment, respectively. | ClinicalTrials.gov |
| Secondary | Visoconstructive function | 36 months | It will be measured by Rey-Osterrieth Complex Figure. Minimum/maximum scale values (0-36), where 36 is a better visoconstructive function. | ClinicalTrials.gov |
| Secondary | Selective and alternating attention | 36 months | It will be measured by Trail making test (Part A and B). | ClinicalTrials.gov |
| Secondary | Attention and working memory | 36 months | It will be measured by the Digits subtest of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV). This subtest includes two parts: Digits Forward (measuring attention) and Digits Backward (measuring working memory). The total raw score ranges from 0 (minimum) to 30 (maximum), with higher scores indicating better attention and working memory capacity. | ClinicalTrials.gov |
| Secondary | Inhibition | 36 months | It will be measured by Stroop Color-Word Test. | ClinicalTrials.gov |
| Secondary | Phonemic verbal fluency | 36 months | It will be measured by PMR. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 31
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 15630418 | BACKGROUND | PubMed |
| 16731815 | BACKGROUND | PubMed |
| 22450854 | BACKGROUND | PubMed |
| 25520251 | BACKGROUND | PubMed |
| 26406372 | BACKGROUND | PubMed |
| 27100200 | BACKGROUND | PubMed |
| 29273717 | BACKGROUND | PubMed |
| 29795158 | BACKGROUND | PubMed |
| 29872139 | BACKGROUND | PubMed |
| 30256726 | BACKGROUND | PubMed |
| 30504920 | BACKGROUND | PubMed |
| 31085992 | BACKGROUND | PubMed |
| 31194997 | BACKGROUND | PubMed |
| 31441644 | BACKGROUND | PubMed |
| 31935195 | BACKGROUND | PubMed |
| 32479774 | BACKGROUND | PubMed |
| 32665548 | BACKGROUND | PubMed |
| 33027674 | BACKGROUND | PubMed |
| 33164939 | BACKGROUND | PubMed |
| 33473210 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)